NCT05113368 - Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

February 28, 2027

Conditions

Ovarian CancerSerous Ovarian Cancer

Interventions

DRUG

Regorafenib

Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities

DRUG

Fulvestrant

500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities

Trial Locations (1)

44106

RECRUITING

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland